Skip to main content
Top
Published in: Clinical and Experimental Nephrology 3/2008

01-06-2008 | Review article

A peritoneal-based automated wearable artificial kidney

Authors: David B. N. Lee, Martin Roberts

Published in: Clinical and Experimental Nephrology | Issue 3/2008

Login to get access

Abstract

Work on wearable kidneys has evolved around the technology of hemodialysis or hemofiltration, which call for continuous anticoagulation of the extracoporeal circulation and are encumbered with potential immunologic and non-immunologic complications of continuous blood–artificial membrane interactions. A peritoneal-based automated wearable artificial kidney (AWAK) requires no extracorporeal circulation and is therefore “bloodless.” Because AWAK is designed to continuously regenerate and reuse the spent dialysate in perpetuity, it is also “waterless.” A sorbent-based assembly regenerates both the aqueous and the protein components (AqC and PrC) of the spent dialysate, producing a novel, autologous protein-containing dialysate. The regenerated AqC has the same composition as the commercially available peritoneal dialysate, but contains bicarbonate instead of lactate and has a more physiological pH. The regenerated PrC is recycled back into the peritoneal cavity, thereby ameliorating or eliminating protein loss. Depending on the steady-state protein concentrations that can be achieved (under the condition of continuous dialysate regeneration and recycling), the PrC also has the potential of both augmenting ultrafiltration and mediating the removal of protein-bound toxins. Additional sorbents can be incorporated into AWAK for the removal of middle molecular weight uremic toxins. At a regeneration rate of 4 l/h, AWAK provides a dialysate flow of 96 l/day (8–12 times the current rate). Round-the-clock dialysis and ultrafiltration provide steady-state metabolic-biochemical and fluid balance regulation, thereby eliminating “shocks” of abrupt changes in these parameters that characterize the current dialytic modalities. Dialysis-on-the-go, made possible by AWAK’s “wearability” and automation, frees end-stage renal failure patients from the servitude that is demanded by the current dialytic regimentations.
Literature
1.
go back to reference Vanholder R, De Smet R, Glorieux G, et al. Review on uremic toxins: classification, concentration, and interindividual variability. Kidney Int. 2003;63(5):1934–43.PubMedCrossRef Vanholder R, De Smet R, Glorieux G, et al. Review on uremic toxins: classification, concentration, and interindividual variability. Kidney Int. 2003;63(5):1934–43.PubMedCrossRef
2.
go back to reference Gura V, Beizai M, Ezon C, Polaschegg HD. Continuous renal replacement therapy for end-stage renal disease. The wearable artificial kidney (WAK). Contrib Nephrol. 2005;149:325–33.PubMed Gura V, Beizai M, Ezon C, Polaschegg HD. Continuous renal replacement therapy for end-stage renal disease. The wearable artificial kidney (WAK). Contrib Nephrol. 2005;149:325–33.PubMed
3.
go back to reference Nissenson AR, Ronco C, Pergamit G, Edelstein M, Watts R. The human nephron filter: toward a continuously functioning, implantable artificial nephron system. Blood Purif. 2005;23(4):269–74.PubMedCrossRef Nissenson AR, Ronco C, Pergamit G, Edelstein M, Watts R. The human nephron filter: toward a continuously functioning, implantable artificial nephron system. Blood Purif. 2005;23(4):269–74.PubMedCrossRef
4.
go back to reference Saito A, Aung T, Sekiguchi K, et al. Present status and perspectives of bioartificial kidneys. J Artif Organs. 2006;9(3):130–5.PubMedCrossRef Saito A, Aung T, Sekiguchi K, et al. Present status and perspectives of bioartificial kidneys. J Artif Organs. 2006;9(3):130–5.PubMedCrossRef
5.
go back to reference Lande AJ, Roberts M, Pecker EA. In search of a 24 hrs/day, 7 days/week wearable hemodialyzer. Trans Am Soc Artif Intern Organs. 1977;23:185–90.PubMed Lande AJ, Roberts M, Pecker EA. In search of a 24 hrs/day, 7 days/week wearable hemodialyzer. Trans Am Soc Artif Intern Organs. 1977;23:185–90.PubMed
6.
go back to reference Yamamoto K, Hiwatari M, Kohori F, Sakai K, Fukuda M, Hiyoshi T. Membrane fouling and dialysate flow pattern in an internal filtration-enhancing dialyzer. J Artif Organs. 2005;8(3):198–205.PubMedCrossRef Yamamoto K, Hiwatari M, Kohori F, Sakai K, Fukuda M, Hiyoshi T. Membrane fouling and dialysate flow pattern in an internal filtration-enhancing dialyzer. J Artif Organs. 2005;8(3):198–205.PubMedCrossRef
7.
go back to reference Murisasco A, Reynier JP, Ragon A, et al. Continuous arterio-venous hemofiltration in a wearable device to treat end-stage renal disease. ASAIO Trans. 1986;32(1):567–71.PubMedCrossRef Murisasco A, Reynier JP, Ragon A, et al. Continuous arterio-venous hemofiltration in a wearable device to treat end-stage renal disease. ASAIO Trans. 1986;32(1):567–71.PubMedCrossRef
8.
go back to reference Neff MS, Sadjadi S, Slifkin R. A wearable artificial glorerulus. ASAIO Trans. 1979;25:71–3. Neff MS, Sadjadi S, Slifkin R. A wearable artificial glorerulus. ASAIO Trans. 1979;25:71–3.
9.
go back to reference Lee DBN, Roberts M. A peritoneal-based wearable dialysis system. Continuous dialysis using a protein-containing dialysate In: Agarwal S, ed. Scientific Proceedings, South-Asian Nephrology Congress at New Millennium and International CME-2000. New Delhi, 2000:94–9. Lee DBN, Roberts M. A peritoneal-based wearable dialysis system. Continuous dialysis using a protein-containing dialysate In: Agarwal S, ed. Scientific Proceedings, South-Asian Nephrology Congress at New Millennium and International CME-2000. New Delhi, 2000:94–9.
10.
go back to reference Roberts M, Lee DBN. A proposed peritoneal-based wearable artificial kidney. Home Hemodialysis Int. 1999;3:65–7. Roberts M, Lee DBN. A proposed peritoneal-based wearable artificial kidney. Home Hemodialysis Int. 1999;3:65–7.
11.
go back to reference Roberts M, Lee DBN. Wearable artificial kidneys. A peritoneal-dialysis approach. Dialysis and Transplantation. 2006;36:780–2.CrossRef Roberts M, Lee DBN. Wearable artificial kidneys. A peritoneal-dialysis approach. Dialysis and Transplantation. 2006;36:780–2.CrossRef
12.
go back to reference Roberts M, Niu PC, Lee DBN. Regeneration of peritoneal dialysate (PD): a step towards a continuous wearable artificial kidney (CWAK). J Am Soc Nephrol. 1991;2(3):367. Roberts M, Niu PC, Lee DBN. Regeneration of peritoneal dialysate (PD): a step towards a continuous wearable artificial kidney (CWAK). J Am Soc Nephrol. 1991;2(3):367.
13.
go back to reference Vychytil A, Horl WH. The role of tidal peritoneal dialysis in modern practice: A European perspective. Kidney Int Suppl. 2006(103):S96–103.CrossRef Vychytil A, Horl WH. The role of tidal peritoneal dialysis in modern practice: A European perspective. Kidney Int Suppl. 2006(103):S96–103.CrossRef
14.
go back to reference Fernando SK, Finkelstein FO. Tidal PD: its role in the current practice of peritoneal dialysis. Kidney Int Suppl 2006(103):S91–5.PubMedCrossRef Fernando SK, Finkelstein FO. Tidal PD: its role in the current practice of peritoneal dialysis. Kidney Int Suppl 2006(103):S91–5.PubMedCrossRef
15.
go back to reference Roberts M, Ash SR, Lee DB. Innovative peritoneal dialysis: flow-thru and dialysate regeneration. ASAIO J. 1999;45(5):372–8.PubMedCrossRef Roberts M, Ash SR, Lee DB. Innovative peritoneal dialysis: flow-thru and dialysate regeneration. ASAIO J. 1999;45(5):372–8.PubMedCrossRef
16.
go back to reference Villarroel F. Kinetics of intermittent and continuous peritoneal dialysis. J Dial. 1977;1(4):333–47.PubMed Villarroel F. Kinetics of intermittent and continuous peritoneal dialysis. J Dial. 1977;1(4):333–47.PubMed
17.
go back to reference Lange K, Treser G, Mangalat J. Automatic continuous high flow rate peritoneal dialysis. Arch Klin Med. 1968;214(3):201–6.PubMed Lange K, Treser G, Mangalat J. Automatic continuous high flow rate peritoneal dialysis. Arch Klin Med. 1968;214(3):201–6.PubMed
18.
go back to reference Lee DB, Brown DL, Baker LR, Littlejohns DW, Roberts PD. Haematological complications of chlorate poisoning. Br Med J. 1970;2(5700):31–2.PubMed Lee DB, Brown DL, Baker LR, Littlejohns DW, Roberts PD. Haematological complications of chlorate poisoning. Br Med J. 1970;2(5700):31–2.PubMed
19.
go back to reference Blumenkrantz MJ, Gordon A, Roberts M, Lewin AJ, Pecker EA, Moran JK, Coburn JW, Maxwell MH. Applications of the Redy sorbent system to hemodialysis and peritoneal dialysis. Artif Organs. 1979;3(3):230–6.PubMedCrossRef Blumenkrantz MJ, Gordon A, Roberts M, Lewin AJ, Pecker EA, Moran JK, Coburn JW, Maxwell MH. Applications of the Redy sorbent system to hemodialysis and peritoneal dialysis. Artif Organs. 1979;3(3):230–6.PubMedCrossRef
20.
go back to reference Hansen S. Sorbent dialysis in the third millennium. Nephrol News Issues 2006;20(1):43–5.PubMed Hansen S. Sorbent dialysis in the third millennium. Nephrol News Issues 2006;20(1):43–5.PubMed
21.
go back to reference Capparelli AW, Roberts M, Lee DBN. Towards a wearable artificial kidney for continuous dialysis: ex-vivo sorbent regeneration of filtered peritoneal dialysate during intermittent peritoneal dialysis. J Am Soc Nephr. 1993;4:399A. Capparelli AW, Roberts M, Lee DBN. Towards a wearable artificial kidney for continuous dialysis: ex-vivo sorbent regeneration of filtered peritoneal dialysate during intermittent peritoneal dialysis. J Am Soc Nephr. 1993;4:399A.
22.
go back to reference Hoff CM. In vitro biocompatibility performance of Physioneal. Kidney Int Suppl. 2003(88):S57–74.CrossRef Hoff CM. In vitro biocompatibility performance of Physioneal. Kidney Int Suppl. 2003(88):S57–74.CrossRef
23.
go back to reference Etteldorf JN, Dobbins WT, Summitt RL, Rainwater WT, Fischer RL. Intermittent peritoneal dialysis using 5 per cent albumin in the treatment of salicylate intoxication in children. J Pediatr. 1961;58:226–36.PubMedCrossRef Etteldorf JN, Dobbins WT, Summitt RL, Rainwater WT, Fischer RL. Intermittent peritoneal dialysis using 5 per cent albumin in the treatment of salicylate intoxication in children. J Pediatr. 1961;58:226–36.PubMedCrossRef
24.
go back to reference Roberts M, Dinovo EC, Yanagawa N, Lee DBN. Can peritoneal proteins be regenerated and reused for binding toxins? J Am Soc Nephrol. 1999;10:228A. Roberts M, Dinovo EC, Yanagawa N, Lee DBN. Can peritoneal proteins be regenerated and reused for binding toxins? J Am Soc Nephrol. 1999;10:228A.
25.
go back to reference Roberts M, Paul W, Yanagawa N, Corry DB, Lee DBN. Peritoneal dialysis of protein-bound toxins: feasibility of regeneration of spent dialysis proteins. Perit Dial Int. 1999;19(Suppl 1):S22. Roberts M, Paul W, Yanagawa N, Corry DB, Lee DBN. Peritoneal dialysis of protein-bound toxins: feasibility of regeneration of spent dialysis proteins. Perit Dial Int. 1999;19(Suppl 1):S22.
26.
go back to reference Roberts M, Capparelli AW, Wong C, Lee DBN. Development of a wearable artificial kidney based upon sorbent regeneration of peritoneal dialysate. Perit Dial Int. 1995;15(Suppl 4):S88. Roberts M, Capparelli AW, Wong C, Lee DBN. Development of a wearable artificial kidney based upon sorbent regeneration of peritoneal dialysate. Perit Dial Int. 1995;15(Suppl 4):S88.
27.
go back to reference Petersen NJ, Carson LA, Favero MS, Marshall JH Jr, Aguero SM. Removal of bacteria and bacterial endotoxin from dialysis fluids by the media in a sorbent cartridge. Trans Am Soc Artif Intern Organs. 1979;25:402–3.PubMed Petersen NJ, Carson LA, Favero MS, Marshall JH Jr, Aguero SM. Removal of bacteria and bacterial endotoxin from dialysis fluids by the media in a sorbent cartridge. Trans Am Soc Artif Intern Organs. 1979;25:402–3.PubMed
28.
go back to reference Levy E. Method of reducing contaminants in drinking water In: USPaT Office, ed. United States Patent Application Publication. USA, 2003. Levy E. Method of reducing contaminants in drinking water In: USPaT Office, ed. United States Patent Application Publication. USA, 2003.
29.
go back to reference Karl DW, Magnusson JC, Carr PW, Flickinger MC. Preliminary assessment of removal of pyrogenic lipopolysaccharides with colloidal zirconia adsorbents. Enzyme Microb Technol. 1991;13(9):708–15.PubMedCrossRef Karl DW, Magnusson JC, Carr PW, Flickinger MC. Preliminary assessment of removal of pyrogenic lipopolysaccharides with colloidal zirconia adsorbents. Enzyme Microb Technol. 1991;13(9):708–15.PubMedCrossRef
30.
go back to reference Sonderstrup J. On bacteriological problems in the REDY dialysis system. Scand J Urol Nephrol 1976(30 Suppl):19–22. Sonderstrup J. On bacteriological problems in the REDY dialysis system. Scand J Urol Nephrol 1976(30 Suppl):19–22.
31.
go back to reference Murisasco A, Baz M, Boobes Y, Bertocchio P, el Mehdi M, Durand C, Reynier JP, Ragon A. A continuous hemofiltration system using sorbents for hemofiltrate regeneration. Clin Nephrol. 1986;26(Suppl 1):S53–7.PubMed Murisasco A, Baz M, Boobes Y, Bertocchio P, el Mehdi M, Durand C, Reynier JP, Ragon A. A continuous hemofiltration system using sorbents for hemofiltrate regeneration. Clin Nephrol. 1986;26(Suppl 1):S53–7.PubMed
32.
go back to reference Shapiro WB, Schilb TP, Porush JG. Sorbent recycling of ultrafiltrate in man–a 45-week crossover study. Clin Nephrol. 1986;26(Suppl 1):S47–52.PubMed Shapiro WB, Schilb TP, Porush JG. Sorbent recycling of ultrafiltrate in man–a 45-week crossover study. Clin Nephrol. 1986;26(Suppl 1):S47–52.PubMed
33.
go back to reference Twardowski ZJ. Short, thrice-weekly hemodialysis is inadequate regardless of small molecule clearance. Int J Artif Organs. 2004;27(6):452–66.PubMed Twardowski ZJ. Short, thrice-weekly hemodialysis is inadequate regardless of small molecule clearance. Int J Artif Organs. 2004;27(6):452–66.PubMed
34.
go back to reference Frampton JE, Plosker GL. Icodextrin: a review of its use in peritoneal dialysis. Drugs. 2003;63(19):2079–105.PubMedCrossRef Frampton JE, Plosker GL. Icodextrin: a review of its use in peritoneal dialysis. Drugs. 2003;63(19):2079–105.PubMedCrossRef
35.
go back to reference Garcia-Lopez E, Lindholm B, Tranaeus A. Biocompatibility of new peritoneal dialysis solutions: clinical experience. Perit Dial Int. 2000;20(Suppl 5):S48–56.PubMed Garcia-Lopez E, Lindholm B, Tranaeus A. Biocompatibility of new peritoneal dialysis solutions: clinical experience. Perit Dial Int. 2000;20(Suppl 5):S48–56.PubMed
36.
go back to reference Rozenberg R, Magen E, Weissgarten J, Korzets Z. Icodextrin-induced sterile peritonitis: the Israeli experience. Perit Dial Int. 2006;26(3):402–5.PubMed Rozenberg R, Magen E, Weissgarten J, Korzets Z. Icodextrin-induced sterile peritonitis: the Israeli experience. Perit Dial Int. 2006;26(3):402–5.PubMed
37.
go back to reference Lai KN, Ho SK, Leung J, Tang SC, Chan TM, Li FK. Increased survival of mesothelial cells from the peritoneum in peritoneal dialysis fluid. Cell Biol Int. 2001;25(5):445–50.PubMedCrossRef Lai KN, Ho SK, Leung J, Tang SC, Chan TM, Li FK. Increased survival of mesothelial cells from the peritoneum in peritoneal dialysis fluid. Cell Biol Int. 2001;25(5):445–50.PubMedCrossRef
38.
go back to reference Etteldorf JN, Montalvo JM, Kaplan S, Sheffield JA. Intermittent peritoneal dialysis in the treatment of experimental salicylate intoxication. J Pediatr. 1960;56:1–10.PubMedCrossRef Etteldorf JN, Montalvo JM, Kaplan S, Sheffield JA. Intermittent peritoneal dialysis in the treatment of experimental salicylate intoxication. J Pediatr. 1960;56:1–10.PubMedCrossRef
39.
go back to reference Chiu A, Fan ST. MARS in the treatment of liver failure: controversies and evidence. Int J Artif Organs. 2006;29(7):660–7.PubMed Chiu A, Fan ST. MARS in the treatment of liver failure: controversies and evidence. Int J Artif Organs. 2006;29(7):660–7.PubMed
40.
go back to reference Bammens B, Evenepoel P, Verbeke K, Vanrenterghem Y. Removal of middle molecules and protein-bound solutes by peritoneal dialysis and relation with uremic symptoms. Kidney Int. 2003;64(6):2238–43.PubMedCrossRef Bammens B, Evenepoel P, Verbeke K, Vanrenterghem Y. Removal of middle molecules and protein-bound solutes by peritoneal dialysis and relation with uremic symptoms. Kidney Int. 2003;64(6):2238–43.PubMedCrossRef
41.
go back to reference Faybik P, Hetz H, Baker A, Bittermann C, Berlakovich G, Werba A, Krenn CG, Steltzer H. Extracorporeal albumin dialysis in patients with Amanita phalloides poisoning. Liver Int. 2003;23(Suppl 3):28–33.PubMed Faybik P, Hetz H, Baker A, Bittermann C, Berlakovich G, Werba A, Krenn CG, Steltzer H. Extracorporeal albumin dialysis in patients with Amanita phalloides poisoning. Liver Int. 2003;23(Suppl 3):28–33.PubMed
42.
go back to reference Yokoyama K, Ogura Y, Kishimoto M, et al. Blood purification for severe sarin poisoning after the Tokyo subway attack. Jama. 1995;274(5):379.PubMedCrossRef Yokoyama K, Ogura Y, Kishimoto M, et al. Blood purification for severe sarin poisoning after the Tokyo subway attack. Jama. 1995;274(5):379.PubMedCrossRef
43.
go back to reference Ash SR, Sullivan TA, Carr DJ. Sorbent suspensions vs. sorbent columns for extracorporeal detoxification in hepatic failure. Ther Apher Dial. 2006;10(2):145–53.PubMedCrossRef Ash SR, Sullivan TA, Carr DJ. Sorbent suspensions vs. sorbent columns for extracorporeal detoxification in hepatic failure. Ther Apher Dial. 2006;10(2):145–53.PubMedCrossRef
44.
go back to reference Winchester JF, Amerling R, Harbord N, Capponi V, Ronco C. The potential application of sorbents in peritoneal dialysis. Contrib Nephrol. 2006;150:336–43.PubMedCrossRef Winchester JF, Amerling R, Harbord N, Capponi V, Ronco C. The potential application of sorbents in peritoneal dialysis. Contrib Nephrol. 2006;150:336–43.PubMedCrossRef
45.
go back to reference Tauer A, Zhang X, Schaub TP, Zimmeck T, Niwa T, Passlick-Deetjen J, Pischetsrieder M. Formation of advanced glycation end products during CAPD. Am J Kidney Dis. 2003;41(3 Suppl 1):S57–60.PubMedCrossRef Tauer A, Zhang X, Schaub TP, Zimmeck T, Niwa T, Passlick-Deetjen J, Pischetsrieder M. Formation of advanced glycation end products during CAPD. Am J Kidney Dis. 2003;41(3 Suppl 1):S57–60.PubMedCrossRef
46.
go back to reference Reddingius RE, de Boer AW, Schroder CH, Willems JL, Monnens LA. Increase of the bioavailability of intraperitoneal erythropoietin in children on peritoneal dialysis by administration in small dialysis bags. Perit Dial Int. 1997;17(5):467–70.PubMed Reddingius RE, de Boer AW, Schroder CH, Willems JL, Monnens LA. Increase of the bioavailability of intraperitoneal erythropoietin in children on peritoneal dialysis by administration in small dialysis bags. Perit Dial Int. 1997;17(5):467–70.PubMed
47.
go back to reference Schroder CH, Swinkels LM, Reddingius RE, Sweep FG, Willems HL, Monnens LA. Adsorption of erythropoietin and growth hormone to peritoneal dialysis bags and tubing. Perit Dial Int. 2001;21(1):90–2.PubMed Schroder CH, Swinkels LM, Reddingius RE, Sweep FG, Willems HL, Monnens LA. Adsorption of erythropoietin and growth hormone to peritoneal dialysis bags and tubing. Perit Dial Int. 2001;21(1):90–2.PubMed
48.
go back to reference Schroder CH. The management of anemia in pediatric peritoneal dialysis patients. Guidelines by an ad hoc European committee. Pediatr Nephrol. 2003;18(8):805–9.PubMedCrossRef Schroder CH. The management of anemia in pediatric peritoneal dialysis patients. Guidelines by an ad hoc European committee. Pediatr Nephrol. 2003;18(8):805–9.PubMedCrossRef
49.
go back to reference Ghosh S, Sharma A, Talukder G. Zirconium. An abnormal trace element in biology. Biol Trace Elem Res. 1992;35(3):247–71.PubMedCrossRef Ghosh S, Sharma A, Talukder G. Zirconium. An abnormal trace element in biology. Biol Trace Elem Res. 1992;35(3):247–71.PubMedCrossRef
50.
go back to reference Schroeder HA, Balassa JJ. Abnormal trace metals in man: zirconium. J Chronic Dis. 1966;19(5):573–86.PubMedCrossRef Schroeder HA, Balassa JJ. Abnormal trace metals in man: zirconium. J Chronic Dis. 1966;19(5):573–86.PubMedCrossRef
51.
52.
go back to reference Sollazzo V, Palmieri A, Pezzetti F, Bignozzi CA, Argazzi R, Massari L, Brunelli G, Carinci F. Genetic effect of zirconium oxide coating on osteoblast-like cells. J Biomed Mater Res B Appl Biomater 2007. Sollazzo V, Palmieri A, Pezzetti F, Bignozzi CA, Argazzi R, Massari L, Brunelli G, Carinci F. Genetic effect of zirconium oxide coating on osteoblast-like cells. J Biomed Mater Res B Appl Biomater 2007.
53.
go back to reference Laden K. Introduction ahd history of antiperspirants and deodorants. In: Laden K, Felger CB, eds. Antiperspirants and deodorants. New York: Marcel Decker, 1988:1–13. Laden K. Introduction ahd history of antiperspirants and deodorants. In: Laden K, Felger CB, eds. Antiperspirants and deodorants. New York: Marcel Decker, 1988:1–13.
54.
go back to reference Chang PP, Henegbarth EA, Lang LA. Maxillary zirconia implant fixed partial dentures opposing an acrylic resin implant fixed complete denture: a two-year clinical report. J Prosthet Dent. 2007;97(6):321–30.PubMedCrossRef Chang PP, Henegbarth EA, Lang LA. Maxillary zirconia implant fixed partial dentures opposing an acrylic resin implant fixed complete denture: a two-year clinical report. J Prosthet Dent. 2007;97(6):321–30.PubMedCrossRef
55.
go back to reference Tsukamoto R, Chen S, Asano T, Ogino M, Shoji H, Nakamura T, Clarke IC. Improved wear performance with crosslinked UHMWPE and zirconia implants in knee simulation. Acta Orthop. 2006;77(3):505–11.PubMedCrossRef Tsukamoto R, Chen S, Asano T, Ogino M, Shoji H, Nakamura T, Clarke IC. Improved wear performance with crosslinked UHMWPE and zirconia implants in knee simulation. Acta Orthop. 2006;77(3):505–11.PubMedCrossRef
56.
go back to reference Lappalainen R, Santavirta SS. Potential of coatings in total hip replacement. Clin Orthop Relat Res. 2005(430):72–9.CrossRef Lappalainen R, Santavirta SS. Potential of coatings in total hip replacement. Clin Orthop Relat Res. 2005(430):72–9.CrossRef
57.
go back to reference Schadel A, Thun G, Stork L, Metzler R. Immunodiffusion and immunohistochemical investigations on the reactivity of oxide ceramic middle-ear implants. ORL J Otorhinolaryngol Relat Spec. 1993;55(4):216–21.PubMed Schadel A, Thun G, Stork L, Metzler R. Immunodiffusion and immunohistochemical investigations on the reactivity of oxide ceramic middle-ear implants. ORL J Otorhinolaryngol Relat Spec. 1993;55(4):216–21.PubMed
58.
go back to reference Odell RA. Sorbent dialysis. In: Nissenson AR, Fine RN, Gentile DE, eds. Clinical dialysis, 2nd edition. Connecticut: Appleton and Lange, 1990:712–9. Odell RA. Sorbent dialysis. In: Nissenson AR, Fine RN, Gentile DE, eds. Clinical dialysis, 2nd edition. Connecticut: Appleton and Lange, 1990:712–9.
59.
go back to reference U.S. Renal Data System, USRDS 2006 Annual Data Report: Atlas of End-Stage Renal Disease in the United States. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases. U.S. Renal Data System, USRDS 2006 Annual Data Report: Atlas of End-Stage Renal Disease in the United States. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases.
Metadata
Title
A peritoneal-based automated wearable artificial kidney
Authors
David B. N. Lee
Martin Roberts
Publication date
01-06-2008
Publisher
Springer Japan
Published in
Clinical and Experimental Nephrology / Issue 3/2008
Print ISSN: 1342-1751
Electronic ISSN: 1437-7799
DOI
https://doi.org/10.1007/s10157-008-0050-9

Other articles of this Issue 3/2008

Clinical and Experimental Nephrology 3/2008 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.